A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Nix-TB TRIAL FOR XDR-TB LAUNCHED
TB Alliance has announced the start of the Nix-TB trial, aimed at testing an all-oral drug regimen with the potential to shorten, simplify, and improve treatment for XDR-TB. Nix-TB will study a three-drug regimen of bedaquiline, pretonamid, and linezolid. To read more on the launch of the trial, visit the TB Alliance website here, and the trial factsheet here.
Recent News and Announcements
The WHO Expert Committee on Selection and Use of Essential Medicines has recommended the inclusion of five TB medications in the WHO Model List of Essential Medicines. The recommended drugs include bedaquiline, delamanid, linezolid, rifapentine and terizidone. Rifapentine is indicated for the treatment of TB infection, while the other four medicines are included for the treatment of […]
Phumeza Tisile, an XDR-TB survivor and activist, lost her hearing due to side effects from drugs to treat XDR-TB. Last month, Phumeza received a cochlear implant and was able to hear for the first time in almost five years. Read her post here to hear more about this experience or visit her blog at the MSF […]
On April 1st, the bedaquiline donation program was opened, allowing countries to request bedaquiline. This program is in response to the agreement between The United States Agency for International Development (USAID) and Janssen Therapeutics, to provide the drug free to 30,000 MDR-TB patients in over 100 low- and middle-income countries over a four year period. For […]
endTB, a collaboration between Partners in Health, Médecins Sans Frontières,Interactive Research and Development, and the financial partner UNITAID, will kick off next month. The project aims to radically change the management of MDR-TB and will provide access to new anti-TB drugs to 2,600 patients in 16 countries. Read the press release from MSF here.
We want to hear about your experience! Our aim is to compile experiences of both successful and unsuccessful efforts to gain access to new TB drugs through compassionate use, expanded access, or other pre-approval mechanisms. We hope to gather information on effective strategies and potential roadblocks to accessing new TB drugs. Access our survey here, […]